A ‘cure’ for haemophilia is one step closer, following results of a groundbreaking gene therapy trial led by the NHS in London.
Clinical researchers at Barts Health NHS Trust and Queen Mary University of London have found that over one year on from a single treatment with a gene therapy drug, participants with haemophilia A (the most common type) are showing normal levels of the previously missing protein, and effectively curing them.
A single infusion of the gene therapy drug showed improved levels of the essential blood clotting protein Factor VIII, with 85 per cent of patients achieving normal or near-normal Factor VIII levels even many months after treatment.
The ‘transformational’ results have particular significance as the first successful gene therapy trial for the haemophilia A.
A hereditary genetic condition
There are around 2000 people with severe haemophilia A in the UK. A hereditary genetic condition dominantly affecting men, people with severe haemophilia A have virtually none of the protein factor VIII which is essential for blood to clot. It puts those affected at risk of excessive bleeding even from the slightest injury as well as causing spontaneous internal bleeding, which can be life-threatening. Recurring bleeding into joints can also lead to progressive joint damage and arthritis. The only current treatment involves multiple weekly injections to control and prevent bleeding, but there is no cure.
The trial saw patients across England injected with a copy of the missing gene, which allows their cells to produce the missing clotting factor. Following patients for up to nineteen months, tests show that eleven out of thirteen patients in the trial now have normal or near normal levels of the previously missing factor and all thirteen patients have been able to stop their previously regular treatment.
Professor John Pasi, Haemophilia Centre Director at Barts Health NHS Trust and Professor of Haemostasis and Thrombosis at Queen Mary University of London explained: “We have seen mind-blowing results which have far exceeded our expectations. When we started out we thought it would be a huge achievement to show a five per cent improvement, so to actually be seeing normal or near normal factor levels with dramatic reduction in bleeding is quite simply amazing. We really now have the potential to transform care for people with haemophilia using a single treatment for people who at the moment must inject themselves as often as every other day. It is so exciting.”
The team will now hold further tests widening participants globally to include people in the USA, Europe, Africa and South America.
Professor Pasi continued: “Incredibly exciting is the potential for a significant change in how haemophilia is treated globally. A single dose of medication that can so dramatically improve the lives of patients across the world is an amazing prospect.”
Professor Jo Martin, President, The Royal College of Pathologists said: “Pathology research is often responsible for ground-breaking developments in diagnoses and treatments that transform the lives of patients.
“What is truly remarkable about this revolutionary new gene therapy are the profound life-changing effects it offers patients with haemophilia. We would like to congratulate College fellow, Professor Pasi, and his team at Barts Health NHS Trust and Queen Mary University of London for their work in creating a simple but transformational treatment for patients.”
Jake Omer, 29 lives in Billericay and is married with two children, aged 3 years and a baby of 5 weeks. Diagnosed at two years old, he has had frequent injections of factor VIII to prevent bleeds ever since. Before he was treated with the gene therapy, Jake would wake up early before work to inject three times a week as well as injecting whenever he had an injury to stop the bleeding. As a result of of repeated bleeding Jake has arthritis in his ankles. His father is a Turk-Cypriot and as a child he and his family could never travel to visit relatives in case he needed medical care as the facilities wouldn’t have been available.
Jake said: “The gene therapy has changed my life. I now have hope for my future. It is incredible to now hope that I can play with my kids, kick a ball around and climb trees well into my kids’ teenage years and beyond. The arthritis in my ankles meant I used to worry how far I would be able to walk once I turned 40. At 23 I struggled to run 100m to catch a bus; now at 29 I’m walking two miles every day which I just couldn’t have done before having the gene therapy treatment.
“It’s really strange to not have to worry about bleeding or swellings. The first time I noticed a difference was about four months after the treatment when I dropped a weight in the gym, bashing my elbow really badly. I started to panic thinking this is going to be really bad, but after icing it that night I woke up and it looked normal. That was the moment I saw proof and knew that the gene therapy had worked.”
The Latest on: Haemophilia
Haemophilia A/sialorrhoea: Comparator therapies not implemented, added benefit not proven
on July 9, 2018 at 8:28 am
Two of the four dossier assessments that were published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 2 July 2018, and which deal with completely different therapeutic i... […]
NHS England says yes to Roche's Hemlibra
on July 9, 2018 at 4:00 am
Roche’s new haemophilia A treatment Hemlibra has gained a valuable market access approval from NHS England. The decision is just one of a slew of 'clinical commissioning policy' decisions NHS England ... […]
Rasputin: Lover of the Russian queen
on July 8, 2018 at 2:10 am
The Tsar’s son suffered from haemophilia and his wife, Tsarina Alexandra, became fond of the mystic because she began to believe that he had special healing powers and could cure her son, the Tsarevic... […]
Welfare steps aid his entry into MBBS
on July 6, 2018 at 10:29 am
Haemophilia is a genetic blood disorder in which patients do not have the clotting factor. The only cure is to replenish the blood with the clotting factor. When the government made clotting factors a... […]
4 years on, haemophilia ward yet to be functional
on July 4, 2018 at 7:28 pm
A ward earmarked for haemophilia patients at the Comprehensive Haemophilia Care Centre, Aluva District Hospital, has not become functional, four years after it was opened. A ward with 12 beds was sanc... […]
Inquiry into blood scandal that killed 2,400 to consider attempted cover-up
on July 4, 2018 at 6:38 am
More than 2,400 haemophilia sufferers and other patients lost their lives after being given blood in the 1970s and 80s that was supposed to help treat them. Instead the blood infected them with deadly ... […]
UniQure’s starts pivotal haemophilia B gene therapy trial
on June 29, 2018 at 3:17 am
UniQure has enrolled the first patient in its registration trial of haemophilia B gene therapy candidate AMT-061 as it tries to keep ahead of a rival project from Spark Therapeutics/Pfizer. The subjec... […]
Sobi Emphasises Commitment to Haemophilia Community at WFH 2018 World Congress
on May 20, 2018 at 10:42 pm
STOCKHOLM, May 21, 2018 /PRNewswire/ -- Recent data show quality-of-life improvements for patients treated prophylactically with Elocta® and Alprolix®, extended half-life haemophilia therapies. Swedis... […]
World Haemophilia Day: Replacement therapy at young age can avert disability among patients
on April 18, 2018 at 11:13 pm
On April 17, World Haemophilia Day, let us pledge to work towards making haemophilia in India disability free. By Dr Naresh Gupta Once considered as a 'royal' disease because of its association with t... […]
'Many haemophilia cases go undiagnosed'
on April 14, 2018 at 2:55 pm
MYSURU: Pointing to the availability of free treatment for patients suffering from haemophilia, Karnataka's blood cell nodal officer Dr Swatantra R Bankar on Friday said, "No patient in Karnataka will ... […]
via Google News and Bing News